JP2006526009A5 - - Google Patents

Download PDF

Info

Publication number
JP2006526009A5
JP2006526009A5 JP2006509370A JP2006509370A JP2006526009A5 JP 2006526009 A5 JP2006526009 A5 JP 2006526009A5 JP 2006509370 A JP2006509370 A JP 2006509370A JP 2006509370 A JP2006509370 A JP 2006509370A JP 2006526009 A5 JP2006526009 A5 JP 2006526009A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
cladribine
complex
use according
hydroxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006509370A
Other languages
English (en)
Japanese (ja)
Other versions
JP5412709B2 (ja
JP2006526009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/009384 external-priority patent/WO2004087100A2/en
Publication of JP2006526009A publication Critical patent/JP2006526009A/ja
Publication of JP2006526009A5 publication Critical patent/JP2006526009A5/ja
Application granted granted Critical
Publication of JP5412709B2 publication Critical patent/JP5412709B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006509370A 2003-03-28 2004-03-26 改良された経口及び経粘膜デリバリーのためのクラドリビン製剤 Expired - Lifetime JP5412709B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45892203P 2003-03-28 2003-03-28
US60/458,922 2003-03-28
US48475603P 2003-07-02 2003-07-02
US60/484,756 2003-07-02
US54124604P 2004-02-04 2004-02-04
US60/541,246 2004-02-04
PCT/US2004/009384 WO2004087100A2 (en) 2003-03-28 2004-03-26 Cladribine formulations for improved oral and transmucosal delivery

Publications (3)

Publication Number Publication Date
JP2006526009A JP2006526009A (ja) 2006-11-16
JP2006526009A5 true JP2006526009A5 (cg-RX-API-DMAC7.html) 2011-03-24
JP5412709B2 JP5412709B2 (ja) 2014-02-12

Family

ID=33135981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509370A Expired - Lifetime JP5412709B2 (ja) 2003-03-28 2004-03-26 改良された経口及び経粘膜デリバリーのためのクラドリビン製剤

Country Status (16)

Country Link
US (2) US20070065492A1 (cg-RX-API-DMAC7.html)
EP (1) EP1608343B1 (cg-RX-API-DMAC7.html)
JP (1) JP5412709B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060011943A (cg-RX-API-DMAC7.html)
CN (1) CN101912615B (cg-RX-API-DMAC7.html)
AU (2) AU2004226435B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0408895A (cg-RX-API-DMAC7.html)
CA (1) CA2520522C (cg-RX-API-DMAC7.html)
EA (1) EA009714B1 (cg-RX-API-DMAC7.html)
ES (1) ES2584183T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20050924A2 (cg-RX-API-DMAC7.html)
IS (1) IS8047A (cg-RX-API-DMAC7.html)
ME (1) MEP34508A (cg-RX-API-DMAC7.html)
MX (1) MXPA05010330A (cg-RX-API-DMAC7.html)
NO (1) NO20054944L (cg-RX-API-DMAC7.html)
WO (1) WO2004087100A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2805723T3 (pl) 2004-12-22 2018-04-30 Merck Serono Sa Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
SI1835922T1 (sl) * 2004-12-22 2009-10-31 Merck Serono Sa Kombinacijsko zdravljenje multiple skleroze
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
EP2106786A1 (de) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
JP6234475B2 (ja) 2012-12-11 2017-11-22 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH メラノーマ細胞に対抗するためのデルフィニジン
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
US10493122B2 (en) 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
PT3548091T (pt) 2016-11-29 2022-01-21 Oculis SA Preparação de complexos sólidos de ciclodextrina para administração oftálmica de ingrediente farmacêutico ativo
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
WO2021001366A1 (en) 2019-07-01 2021-01-07 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
JP2024508151A (ja) 2021-03-03 2024-02-22 アレス トレーディング ソシエテ アノニム 自己免疫疾患治療のためのdmdを使用する改善された治療法、並びに該治療法を予測及び/又は最適化するためのバイオマーカー
RU2758436C1 (ru) * 2021-04-05 2021-10-28 Общество с ограниченной ответственностью «ФармЭко» Способ получения аморфных ко-эвапоратов кладрибина с циклодекстринами
US20260000606A1 (en) 2022-06-15 2026-01-01 Vektor Pharma Tf Gmbh Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases
AU2024399689A1 (en) 2023-12-14 2026-07-30 Ares Trading S.A. Cladribine regimen for treating myasthenia gravis

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
HU181703B (en) 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3317064A1 (de) 1983-05-10 1984-11-15 Consortium für elektrochemische Industrie GmbH, 8000 München Verfahren zur herstellung von cyclooctaamylose
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン,ビタミン誘導体,またはホルモンを含有する包接化合物
JP2575460B2 (ja) * 1988-05-12 1997-01-22 東京田辺製薬株式会社 ダナゾール−シクロデキストリン包接化合物
WO1990012035A1 (en) 1989-04-03 1990-10-18 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
JPH035438A (ja) * 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
EP0642347A4 (en) * 1992-05-19 1997-06-18 Scripps Research Inst USE OF 2-HALO-ADENINE DERIVATIVES AS THERAPEUTIC ACTIVE AGENTS AGAINST CHRONIC-MYELOIC LEUKEMIA.
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
CZ154398A3 (cs) * 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
JPH10265495A (ja) * 1997-03-25 1998-10-06 Meiji Milk Prod Co Ltd フルオロプロゲステロン誘導体包接化合物
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP0940157A3 (de) 1998-01-29 2000-06-14 Hans Werner Prof. Lorenzen Vorrichtung zur Stimulation von Körpergewebe
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
US6239118B1 (en) * 1999-10-05 2001-05-29 Richard A. Schatz Method for preventing restenosis using a substituted adenine derivative
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
WO2004087101A2 (en) * 2003-03-28 2004-10-14 Ivax Corporation Oral formulations of cladribine

Similar Documents

Publication Publication Date Title
Robertson et al. On the way to fullerenes: Molecular dynamics study of the curling and closure of graphitic ribbons
CA2520522A1 (en) Cladribine formulations for improved oral and transmucosal delivery
Gordaliza et al. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives
JP2004131682A5 (cg-RX-API-DMAC7.html)
JP2007529544A5 (cg-RX-API-DMAC7.html)
JP2002332234A5 (cg-RX-API-DMAC7.html)
JP2005531584A5 (cg-RX-API-DMAC7.html)
JP2010510221A5 (cg-RX-API-DMAC7.html)
JP2002544250A5 (cg-RX-API-DMAC7.html)
WO2002030466A3 (en) Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
JP2005512925A5 (cg-RX-API-DMAC7.html)
FR2825925B1 (fr) Procede de preparation d'un principe actif a partir de riz, principe actif obtenu et compositions adaptees
JP2007510699A5 (cg-RX-API-DMAC7.html)
JP2005538045A5 (cg-RX-API-DMAC7.html)
JP2003507464A5 (cg-RX-API-DMAC7.html)
JP2004517961A5 (cg-RX-API-DMAC7.html)
JP2007500323A5 (cg-RX-API-DMAC7.html)
JP2009514857A5 (cg-RX-API-DMAC7.html)
JP2007105716A5 (cg-RX-API-DMAC7.html)
JP2005502676A5 (cg-RX-API-DMAC7.html)
JP2007512285A5 (cg-RX-API-DMAC7.html)
CN309247783S (zh) 安抚咬胶防掉链(四)
ATE487810T1 (de) Algainassb-ätzung
CN309541726S (zh) 包装贴(360椰泰0糖生椰)
CN309554522S (zh) 修正带(2803)